

RCE of Application No. 10/060,759
Office Action dated January 17, 2006
Advisory Action dated August 23, 2006
Amendment mailed December 18, 2006

RECEIVED
CENTRAL FAX CENTER
DEC 18 2006

Listing of the Claims:

This listing of claims will replace all prior version, and listings, of claims in the application:

1. (PREVIOUSLY PRESENTED) A method, comprising:
 - (a) providing: i) a patient having symptoms of chronic lymphocytic leukemia, and (ii) a formulation comprising an inhibitor that specifically inhibits Type 4 cyclic adenosine monophosphate phosphodiesterases; and
 - (b) administering a therapeutically effective dose of said formulation to said patient under conditions such that said symptoms are reduced.
2. (ORIGINAL) The method of Claim 1, wherein said administering is enteral administration.
3. (ORIGINAL) The method of Claim 2, wherein said enteral administration is oral administration.
4. (ORIGINAL) The method of Claim 1, wherein said administering is parenteral administration.
5. (ORIGINAL) The method of Claim 1, wherein said patient is a naïve patient.
6. (ORIGINAL) The method of Claim 1, wherein said patient is immunocompromised.

RCE of Application No. 10/060,759
Office Action dated January 17, 2006
Advisory Action dated August 23, 2006
Amendment mailed December 18, 2006

7. (ORIGINAL) The method of Claim 1, wherein said patient is unresponsive to chemotherapy with alkylating agents.

8-14. (CANCELLED)

15. (PREVIOUSLY PRESENTED) A method, comprising:

- (a) providing: i) a patient having symptoms of chronic lymphocytic leukemia, and (ii) a formulation comprising an inhibitor that specifically inhibits Type 4 cyclic adenosine monophosphate phosphodiesterases, wherein said inhibitor is (4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone); and
- (b) administering a therapeutically effective dose of said formulation to said patient under conditions such that said symptoms are reduced.